Amgen's (AMGN) Inflammation Portfolio Could Become an Important Growth Driver - RBC Capital
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $217.00 price target on Amgen (NASDAQ: AMGN) after attending ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
